The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $145.04

Today's change-4.87 -3.25%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $145.04

Today's change-4.87 -3.25%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Amgen Inc down (U.S.)$4.87

Amgen Inc closed sharply lower Friday, dropping (U.S.)$4.87 or 3.25% to (U.S.)$145.04. Over the last five days, shares have lost 5.04% and are down 10.65% for the last year to date. This security has outperformed the S&P 500 by 3.42% during the last year.

Key company metrics

  • Open(U.S.) $148.93
  • Previous close(U.S.) $149.91
  • High(U.S.) $149.39
  • Low(U.S.) $143.69
  • Bid / Ask-- / --
  • YTD % change-10.65%
  • Volume6,451,924
  • Average volume (10-day)4,664,768
  • Average volume (1-month)4,060,164
  • Average volume (3-month)3,915,340
  • 52-week range(U.S.) $130.09 to (U.S.) $181.81
  • Beta0.83
  • Trailing P/E16.00×
  • P/E 1 year forward13.43×
  • Forward PEG1.67×
  • Indicated annual dividend(U.S.) $4.00
  • Dividend yield2.76%
  • Trailing EPS(U.S.) $9.07
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+32.03%

Based on its net profit margin of 32.03%, Amgen Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue5,7235,3705,0335,331
Total other revenue--------
Total revenue5,7235,3705,0335,331
Gross profit4,6894,2814,0004,148
Total cost of revenue1,0341,0891,0331,183
Total operating expense3,3843,2943,0113,872
Selling / general / administrative1,2441,1601,0261,327
Research & development1,1199648941,234
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)681--9
Other operating expenses, total-19--58119
Operating income2,3392,0762,0221,459
Interest income (expense), net non-operating-282-277-252-261
Gain (loss) on sale of assets--------
Other--------
Income before tax2,1921,9971,8761,286
Income after tax1,8631,6531,6231,294
Income tax, total329344253-8
Net income1,8631,6531,6231,294
Total adjustments to net income--------
Net income before extra. items1,8631,6531,6231,294
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,8631,6531,6231,294
Inc. avail. to common incl. extra. items1,8631,6531,6231,294
Diluted net income1,8631,6531,6251,294
Dilution adjustment----2--
Diluted weighted average shares764768770773
Diluted EPS excluding extraordinary itemsvalue per share2.442.152.111.67
Dividends per sharevalue per share0.790.790.790.61
Diluted normalized EPSvalue per share2.452.242.111.68